BOSTON– enGene Holdings Inc., a clinical-stage genetic medicines company, has named Amy Pott as its first Chief Global Commercialization Officer. The appointment comes as the company prepares for a potential Biologics License Application (BLA) submission to the U.S. Food and Drug Administration in 2026 for its lead investigational therapy, detalimogene voraplasmid.
Ms. Pott will oversee global commercialization planning and execution for enGene, reporting directly to CEO Ron Cooper. Her arrival marks a major step forward in the company’s efforts to bring its non-viral gene therapy platform to market, beginning with treatments for Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC).
“Amy brings a rare blend of global commercialization, gene therapy, and analytics expertise,” said Cooper. “Her leadership will be instrumental as we prepare for the next stage of enGene’s growth and the launch of detalimogene.”
Pott joins enGene with more than two decades of experience in biopharma commercialization. Most recently, she served as Senior Vice President of Strategic Brand Marketing for Ophthalmics and Rare Diseases at Astellas Pharma. Prior to that, she led Astellas’ gene therapy commercial strategy and held senior roles at Swedish Orphan Biovitrum, Shire, and Baxalta, with a focus on U.S. and global operations across rare diseases, oncology, and internal medicine.
She holds a Master of Science in European Studies from the London School of Economics and a Bachelor of Arts in History from the University of Bristol.
“I’m excited to join enGene at such a transformative time,” said Pott. “The company’s work in genetic medicine has the potential to redefine treatment for bladder cancer, and I’m honored to be part of that mission.”
enGene’s lead candidate, detalimogene voraplasmid, is being evaluated in the pivotal LEGEND trial, with a BLA filing targeted for mid-2026. The company is positioning itself to move from a clinical-stage innovator to a fully integrated biopharma organization.
